BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014;134:1484-94. [PMID: 24037730 DOI: 10.1002/ijc.28475] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015;10:232-6. [PMID: 25526238 DOI: 10.1097/JTO.0000000000000455] [Cited by in Crossref: 105] [Cited by in F6Publishing: 55] [Article Influence: 15.0] [Reference Citation Analysis]
2 Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016;27 Suppl 3:iii42-50. [PMID: 27573756 DOI: 10.1093/annonc/mdw305] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
3 O'Kane GM, Leighl NB. Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs 2018;32:527-42. [PMID: 29799091 DOI: 10.1007/s40263-018-0526-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
4 Williamson B, Pilla Reddy V. Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs. Biopharm Drug Dispos 2021;42:128-36. [PMID: 33759216 DOI: 10.1002/bdd.2276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17:637-58. [DOI: 10.1038/nrc.2017.84] [Cited by in Crossref: 322] [Cited by in F6Publishing: 328] [Article Influence: 64.4] [Reference Citation Analysis]
6 Krchniakova M, Skoda J, Neradil J, Chlapek P, Veselska R. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration. Int J Mol Sci 2020;21:E3157. [PMID: 32365759 DOI: 10.3390/ijms21093157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Pan L, Zeng K, Wang X, Bi H, Hu H, Huang M, Lou Y, Zeng S. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP. International Journal of Pharmaceutics 2015;496:440-7. [DOI: 10.1016/j.ijpharm.2015.10.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Serritella AV, Bestvina CM. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer. Thorac Surg Clin 2020;30:137-46. [PMID: 32327172 DOI: 10.1016/j.thorsurg.2019.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Remon J, Besse B. Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. Front Oncol. 2018;8:88. [PMID: 29696132 DOI: 10.3389/fonc.2018.00088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
10 van Hoppe S, Schinkel AH. What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters. Pharmacol Res 2017;123:144. [PMID: 28578203 DOI: 10.1016/j.phrs.2017.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 2015;41:412-22. [PMID: 25818541 DOI: 10.1016/j.ctrv.2015.03.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
12 Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther 2015;14:2735-43. [PMID: 26438157 DOI: 10.1158/1535-7163.MCT-15-0553] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 7.1] [Reference Citation Analysis]
13 Schneider M, Schüler J, Höfflin R, Korzeniewski N, Grüllich C, Roth W, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. Urol Oncol 2014;32:877-84. [PMID: 24929890 DOI: 10.1016/j.urolonc.2014.03.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tiotiu A, Billon Y, Vaillant P, Menard O, Hofman P, Mascaux C. [Therapeutic strategies in advanced ALK positive non-small cell lung cancer]. Rev Mal Respir 2019;36:1107-16. [PMID: 31727555 DOI: 10.1016/j.rmr.2019.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Zhao D, Chen J, Chu M, Long X, Wang J. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. Drug Des Devel Ther 2020;14:1663-81. [PMID: 32431491 DOI: 10.2147/DDDT.S249098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res 2015;32:2205-16. [DOI: 10.1007/s11095-014-1609-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
17 Li W, Sparidans RW, Lebre MC, Beijnen JH, Schinkel AH. ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics 2021;13:1761. [PMID: 34834176 DOI: 10.3390/pharmaceutics13111761] [Reference Citation Analysis]
18 Langer O. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions. J Clin Pharmacol 2016;56 Suppl 7:S143-56. [PMID: 27385172 DOI: 10.1002/jcph.722] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
19 Ziogas DC, Tsiara A, Tsironis G, Lykka M, Liontos M, Bamias A, Dimopoulos MA. Treating ALK-positive non-small cell lung cancer. Ann Transl Med 2018;6:141. [PMID: 29862230 DOI: 10.21037/atm.2017.11.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
20 De Carlo E, Stanzione B, Del Conte A, Revelant A, Bearz A. Brigatinib as a treatment of ALK-positive non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development 2021;6:299-305. [DOI: 10.1080/23808993.2021.1954907] [Reference Citation Analysis]
21 Sato T, Ito H, Hirata A, Abe T, Mano N, Yamaguchi H. Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica 2018;48:73-8. [PMID: 28005438 DOI: 10.1080/00498254.2016.1275880] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
22 Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35. [PMID: 25979929 DOI: 10.1158/1078-0432.CCR-14-2791] [Cited by in Crossref: 147] [Cited by in F6Publishing: 92] [Article Influence: 24.5] [Reference Citation Analysis]
23 Durmus S, Hendrikx JJ, Schinkel AH. Apical ABC transporters and cancer chemotherapeutic drug disposition. Adv Cancer Res 2015;125:1-41. [PMID: 25640265 DOI: 10.1016/bs.acr.2014.10.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
24 Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, Chung FT, Fang YF, Guo YK, Yang CT. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer 2021;21:309. [PMID: 33761908 DOI: 10.1186/s12885-021-08005-1] [Reference Citation Analysis]
25 Shao J, Markowitz JS, Bei D, An G. Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 2014;103:3810-33. [DOI: 10.1002/jps.24113] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
26 Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncol 2014;3:61-75. [PMID: 25054901 DOI: 10.2217/cns.13.66] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Strope JD, Peer CJ, Sissung TM, Hall OM, Huang PA, Harris EM, Gustafson KR, Henrich CJ, Sigano DM, Pauly GT, Schneider JP, Bates SE, Figg WD. Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer Biol Ther 2020;21:223-30. [PMID: 31709896 DOI: 10.1080/15384047.2019.1683324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Baik CS, Chamberlain MC, Chow LQ. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2015;10:1268-78. [DOI: 10.1097/jto.0000000000000615] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
29 Khan M, Zhao Z, Arooj S, Zheng T, Liao G. Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:576926. [PMID: 33240815 DOI: 10.3389/fonc.2020.576926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kono Y, Kawahara I, Shinozaki K, Nomura I, Marutani H, Yamamoto A, Fujita T. Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs. Pharmaceutics 2021;13:388. [PMID: 33804018 DOI: 10.3390/pharmaceutics13030388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Pellerino A, Bertero L, Rudà R, Soffietti R. Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. Ther Adv Neurol Disord 2018;11:1756286418759618. [PMID: 29535794 DOI: 10.1177/1756286418759618] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
32 Wang Y, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. Br J Pharmacol 2020;177:3060-74. [PMID: 32087611 DOI: 10.1111/bph.15034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Wierdl M, Tsurkan L, Chi L, Hatfield MJ, Tollemar V, Bradley C, Chen X, Qu C, Potter PM. Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 2018;82:251-63. [PMID: 29855693 DOI: 10.1007/s00280-018-3615-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Khalifa J, Amini A, Popat S, Gaspar LE, Faivre-finn C. Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. Journal of Thoracic Oncology 2016;11:1627-43. [DOI: 10.1016/j.jtho.2016.06.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
35 Jung D, Han JM, Yee J, Kim JY, Gwak HS. Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol 2018;35. [DOI: 10.1007/s12032-018-1213-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
36 Ogihara T, Mizoi K, Kamioka H, Yano K. Physiological Roles of ERM Proteins and Transcriptional Regulators in Supporting Membrane Expression of Efflux Transporters as Factors of Drug Resistance in Cancer. Cancers (Basel) 2020;12:E3352. [PMID: 33198344 DOI: 10.3390/cancers12113352] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
37 Libiad Y, Boutayeb S, Chaibi A. [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma]. Bull Cancer 2022:S0007-4551(22)00010-8. [PMID: 35105467 DOI: 10.1016/j.bulcan.2021.11.019] [Reference Citation Analysis]
38 Wang Y, Sparidans RW, Potters S, Şentürk R, Lebre MC, Beijnen JH, Schinkel AH. P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals (Basel) 2021;14:1087. [PMID: 34832869 DOI: 10.3390/ph14111087] [Reference Citation Analysis]
39 Spagnuolo A, Muto M, Monaco F, Colantuoni G, Gridelli C. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Transl Lung Cancer Res 2019;8:1134-51. [PMID: 32010591 DOI: 10.21037/tlcr.2019.12.24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. The Lancet Oncology 2015;16:e510-21. [DOI: 10.1016/s1470-2045(15)00013-3] [Cited by in Crossref: 99] [Cited by in F6Publishing: 46] [Article Influence: 14.1] [Reference Citation Analysis]
41 Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacol Res 2018;137:47-55. [PMID: 30253203 DOI: 10.1016/j.phrs.2018.09.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
42 Taillibert S, Chamberlain MC. Leptomeningeal metastasis. Handb Clin Neurol 2018;149:169-204. [PMID: 29307353 DOI: 10.1016/B978-0-12-811161-1.00013-X] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
43 Lee DW, Lee KH, Kim JW, Keam B. Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. Int J Mol Sci 2016;17:E1074. [PMID: 27399673 DOI: 10.3390/ijms17071074] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
44 Metro G, Tazza M, Matocci R, Chiari R, Crinò L. Optimal management of ALK-positive NSCLC progressing on crizotinib. Lung Cancer 2017;106:58-66. [PMID: 28285695 DOI: 10.1016/j.lungcan.2017.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
45 Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci 2018;109:572-80. [PMID: 29336091 DOI: 10.1111/cas.13504] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
46 Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2021;39:1253-63. [PMID: 33646820 DOI: 10.1200/JCO.20.03025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Drizou M, Kotteas EA, Syrigos N. Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. Clin Transl Oncol 2017;19:658-66. [PMID: 28054318 DOI: 10.1007/s12094-016-1605-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
48 Peña-Solórzano D, Stark SA, König B, Sierra CA, Ochoa-Puentes C. ABCG2/BCRP: Specific and Nonspecific Modulators. Med Res Rev 2017;37:987-1050. [PMID: 28005280 DOI: 10.1002/med.21428] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
49 Hira D, Terada T. BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. Biochem Pharmacol 2018;147:201-10. [PMID: 29031817 DOI: 10.1016/j.bcp.2017.10.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
50 Karbownik A, Sobańska K, Płotek W, Grabowski T, Klupczynska A, Plewa S, Grześkowiak E, Szałek E. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Invest New Drugs 2020;38:574-83. [PMID: 31177402 DOI: 10.1007/s10637-019-00806-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Liao BC, Lin CC, Yang JC. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother 2018;19:851-64. [PMID: 29726292 DOI: 10.1080/14656566.2018.1472765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
52 Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, Kalkanis SN, Whitsett TG, Salhia B, Tran NL. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11:203-222. [PMID: 24569448 DOI: 10.1038/nrclinonc.2014.25] [Cited by in Crossref: 147] [Cited by in F6Publishing: 133] [Article Influence: 18.4] [Reference Citation Analysis]
53 Sullivan I, Planchard D. Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer. Future Oncol 2016;12:945-61. [PMID: 26892300 DOI: 10.2217/fon.16.15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
54 Wu CP, Hung CY, Murakami M, Wu YS, Lin CL, Huang YH, Hung TH, Yu JS, Ambudkar SV. P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells. Cancers (Basel) 2022;14:2341. [PMID: 35565470 DOI: 10.3390/cancers14092341] [Reference Citation Analysis]
55 Ulahannan D, Khalifa J, Faivre-Finn C, Lee SM. Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. Ann Oncol 2017;28:2923-31. [PMID: 29045549 DOI: 10.1093/annonc/mdx481] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
56 Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Des Devel Ther 2017;11:2047-63. [PMID: 28740365 DOI: 10.2147/DDDT.S113500] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
57 Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol 2017;19:i1-i24. [PMID: 28031389 DOI: 10.1093/neuonc/now197] [Cited by in Crossref: 91] [Cited by in F6Publishing: 76] [Article Influence: 18.2] [Reference Citation Analysis]
58 Wang Y, Sparidans RW, Potters S, Lebre MC, Beijnen JH, Schinkel AH. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacol Res 2021;172:105850. [PMID: 34450308 DOI: 10.1016/j.phrs.2021.105850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Fujita K, Matsumoto N, Ishida H, Kubota Y, Iwai S, Shibanuma M, Kato Y. Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure. Curr Drug Metab 2019;20:361-76. [PMID: 30947665 DOI: 10.2174/1389200220666190402143125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
60 Neul C, Schaeffeler E, Sparreboom A, Laufer S, Schwab M, Nies AT. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends Pharmacol Sci 2016;37:904-32. [PMID: 27659854 DOI: 10.1016/j.tips.2016.08.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
61 Sie M, den Dunnen WF, Lourens HJ, Meeuwsen-de Boer TG, Scherpen FJ, Zomerman WW, Kampen KR, Hoving EW, de Bont ES. Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. PLoS One 2015;10:e0122555. [PMID: 25799134 DOI: 10.1371/journal.pone.0122555] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
62 Peng X, Li L, Ren Y, Xue H, Liu J, Wen S, Chen J. Synthesis of N ‐Carbonyl Acridanes as Highly Potent Inhibitors of Tubulin Polymerization via One‐Pot Copper‐Catalyzed Dual Arylation of Nitriles with Cyclic Diphenyl Iodoniums. Adv Synth Catal 2020;362:2030-8. [DOI: 10.1002/adsc.201901460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Int J Cancer 2018;143:2029-38. [PMID: 29744867 DOI: 10.1002/ijc.31582] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
64 Heigener DF, Reck M. Lung cancer in 2017: Giant steps and stumbling blocks. Nat Rev Clin Oncol 2018;15:71-2. [PMID: 29158589 DOI: 10.1038/nrclinonc.2017.178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
65 Basseville A, Hall MD, Chau CH, Robey RW, Gottesman M, Figg WD, Bates SE. The ABCG2 Multidrug Transporter. In: George AM, editor. ABC Transporters - 40 Years on. Cham: Springer International Publishing; 2016. pp. 195-226. [DOI: 10.1007/978-3-319-23476-2_9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
66 Russo A, Franchina T, Ricciardi GR, Ferraro G, Scimone A, Bronte G, Russo A, Rolfo C, Adamo V. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Rev Anticancer Ther 2016;16:615-23. [PMID: 27109446 DOI: 10.1080/14737140.2016.1182427] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
67 Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacology & Therapeutics 2017;173:58-66. [DOI: 10.1016/j.pharmthera.2017.02.006] [Cited by in Crossref: 122] [Cited by in F6Publishing: 114] [Article Influence: 24.4] [Reference Citation Analysis]
68 Sakamoto H, Yanagitani N, Manabe R, Tsugitomi R, Ogusu S, Tozuka T, Yoshida H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Tasaka S, Nishio M. Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib. Cancer Rep (Hoboken) 2021;:e1414. [PMID: 33960745 DOI: 10.1002/cnr2.1414] [Reference Citation Analysis]
69 Tsakonas G, De Petris L, Ekman S. Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies. Cancer Treatment Reviews 2017;54:122-31. [DOI: 10.1016/j.ctrv.2017.02.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
70 De Carlo E, Del Savio MC, Polesel J, Da Ros V, Berto E, Santarossa S, Chimienti E, Fratino L, Bearz A. Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. Oncotarget 2018;9:15340-9. [PMID: 29632648 DOI: 10.18632/oncotarget.24573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Wang Y, Shen S, Hu P, Geng D, Zheng R, Li X. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence. Cancer Med 2022. [PMID: 35616090 DOI: 10.1002/cam4.4834] [Reference Citation Analysis]
72 Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharm Res 2018;35:177. [PMID: 30003344 DOI: 10.1007/s11095-018-2455-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
73 Katayama R. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. Pharmacol Ther 2017;177:1-8. [PMID: 28185914 DOI: 10.1016/j.pharmthera.2017.02.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
74 Chen W, Jin D, Shi Y, Zhang Y, Zhou H, Li G. The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain. Cancer Med 2020;9:4350-9. [PMID: 32347012 DOI: 10.1002/cam4.3061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Ali R, Arshad J, Palacio S, Mudad R. Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy. Drug Des Devel Ther 2019;13:569-80. [PMID: 30804663 DOI: 10.2147/DDDT.S147499] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
76 Zhang Z, Guo H, Lu Y, Hao W, Han L. Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis. J Thorac Dis 2019;11:1397-409. [PMID: 31179082 DOI: 10.21037/jtd.2019.03.76] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
77 Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18:452-64. [PMID: 29643473 DOI: 10.1038/s41568-018-0005-8] [Cited by in Crossref: 517] [Cited by in F6Publishing: 519] [Article Influence: 172.3] [Reference Citation Analysis]
78 Pinsolle J, McLeer-Florin A, Giaj Levra M, de Fraipont F, Emprou C, Gobbini E, Toffart AC. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Front Med (Lausanne) 2019;6:233. [PMID: 31737634 DOI: 10.3389/fmed.2019.00233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
79 Khan M, Zheng T, Zhao Z, Arooj S, Liao G. Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:586029. [PMID: 33692938 DOI: 10.3389/fonc.2020.586029] [Reference Citation Analysis]
80 Dash RP, Jayachandra Babu R, Srinivas NR. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. Eur J Drug Metab Pharmacokinet 2017;42:915-33. [PMID: 28374336 DOI: 10.1007/s13318-017-0411-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
81 Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet 2021;398:535-54. [PMID: 34273294 DOI: 10.1016/S0140-6736(21)00312-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer 2018;121:37-40. [PMID: 29858024 DOI: 10.1016/j.lungcan.2018.04.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
83 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies. Drug Dev Ind Pharm 2017;43:584-94. [PMID: 28010129 DOI: 10.1080/03639045.2016.1274901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
84 Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model. Mol Cancer Ther 2016;15:819-29. [PMID: 26883271 DOI: 10.1158/1535-7163.MCT-15-0093] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
85 Angeli E, Bousquet G. Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood-Brain Barrier. Pharmaceutics 2021;13:1446. [PMID: 34575525 DOI: 10.3390/pharmaceutics13091446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis F, Battaglin F. Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Saf 2019;42:211-33. [PMID: 30649748 DOI: 10.1007/s40264-018-0780-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
87 Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res 2015;102:200-7. [PMID: 26361725 DOI: 10.1016/j.phrs.2015.09.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
88 Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res 2018;211:57-65. [PMID: 30069759 DOI: 10.1007/978-3-319-91442-8_4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
89 Sissung TM, Goey AK, Ley AM, Strope JD, Figg WD. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol 2014;1175:91-120. [PMID: 25150868 DOI: 10.1007/978-1-4939-0956-8_6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
90 Rong D, Wang C, Zhang X, Wei Y, Zhang M, Liu D, Farhan H, Momen Ali SA, Liu Y, Taouil A, Guo W, Wang Y, Ojima I, Yang S, Wang H. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells. Cancer Lett 2020;491:36-49. [PMID: 32730778 DOI: 10.1016/j.canlet.2020.06.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Tomono T, Yano K, Ogihara T. Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells. Journal of Pharmaceutical Sciences 2017;106:2642-9. [DOI: 10.1016/j.xphs.2017.03.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
92 Di Martino RMC, Bottegoni G, Seghetti F, Russo D, Penna I, De Simone A, Ottonello G, Mandrup Bertozzi S, Armirotti A, Bandiera T, Belluti F, Cavalli A. Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic Evaluation. ChemMedChem 2020;15:949-54. [PMID: 32267999 DOI: 10.1002/cmdc.202000210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
93 Hamilton G, Rath B, Burghuber O. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol 2015;11:835-42. [PMID: 25732197 DOI: 10.1517/17425255.2015.1021685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
94 Huang SH, Huang AC, Wang CC, Chang WC, Liu CY, Pavlidis S, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thorac Cancer 2019;10:2274-81. [PMID: 31613427 DOI: 10.1111/1759-7714.13221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med 2014;7:53-64. [PMID: 24523596 DOI: 10.2147/PGPM.S38295] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
96 Deng J, Shao J, Markowitz JS, An G. ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. Pharm Res 2014;31:2237-55. [DOI: 10.1007/s11095-014-1389-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
97 Paris J, Angeli E, Bousquet G. The Pharmacology of Xenobiotics after Intracerebro Spinal Fluid Administration: Implications for the Treatment of Brain Tumors. Int J Mol Sci 2021;22:1281. [PMID: 33525427 DOI: 10.3390/ijms22031281] [Reference Citation Analysis]
98 Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine 2016;3:54-66. [PMID: 26870817 DOI: 10.1016/j.ebiom.2015.12.009] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 11.3] [Reference Citation Analysis]
99 Hirota T, Muraki S, Ieiri I. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clin Pharmacokinet 2019;58:403-20. [DOI: 10.1007/s40262-018-0689-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
100 van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacol Res 2019;146:104297. [PMID: 31175939 DOI: 10.1016/j.phrs.2019.104297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
101 Jensen KH, Persson G, Storgaard L, Nielsen BB, Pedersen BW, Maroun LL, Huitema A, Pøhl M. Antineoplastic treatment with crizotinib during pregnancy: a case report. Acta Oncol 2019;58:121-2. [PMID: 30101631 DOI: 10.1080/0284186X.2018.1497302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
102 López Brunsó M, Toro Blanch C, Sais Girona E, Roa García D, Hernández Martínez A, Izquierdo Font A, Guerra Prió S, Mas Pueyo HG, Bosch-Barrera J. Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer. Anticancer Drugs 2018;29:380-3. [PMID: 29420339 DOI: 10.1097/CAD.0000000000000600] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
103 Natarajan K, Baer MR, Ross DD. Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance. In: Efferth T, editor. Resistance to Targeted ABC Transporters in Cancer. Cham: Springer International Publishing; 2015. pp. 53-88. [DOI: 10.1007/978-3-319-09801-2_3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
104 Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opin Investig Drugs 2017;26:713-22. [PMID: 28463570 DOI: 10.1080/13543784.2017.1324572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
105 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov 2017;7:137-55. [PMID: 28122866 DOI: 10.1158/2159-8290.CD-16-1123] [Cited by in Crossref: 217] [Cited by in F6Publishing: 114] [Article Influence: 43.4] [Reference Citation Analysis]
106 Bearz A, De Carlo E, Del Conte A, Spina M, Da Ros V, Bertoli E, Revelant A, Stanzione B, Tirelli U. The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation. IJMS 2022;23:7322. [DOI: 10.3390/ijms23137322] [Reference Citation Analysis]
107 Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). Int J Pharm 2020;573:118842. [PMID: 31759109 DOI: 10.1016/j.ijpharm.2019.118842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
108 Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opinion on Emerging Drugs 2018;23:231-41. [DOI: 10.1080/14728214.2018.1527902] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
109 Thai AA, Solomon BJ. Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer? Ann Oncol 2018;29:2160-2. [PMID: 30239586 DOI: 10.1093/annonc/mdy415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]